Key result
Generic ticagrelor achieves bioequivalence to Brilinta across all primary pharmacokinetic parameters.
Why the study?
The study was conducted to investigate the bioequivalence of Anplag 90mg (Ticagrelor) tablet and Brilinta 90 mg (Ticagrelor) tablet under fasting conditions in healthy Pakistani subjects.
Does a generic formulation of ticagrelor 90 mg demonstrate bioequivalence to the reference formulation in healthy subjects?
RCT (n=30)
Open-label
Randomized
No
Does a generic formulation of ticagrelor 90 mg demonstrate bioequivalence to the reference formulation in healthy subjects?
A generic formulation of ticagrelor 90 mg (Anplag) is bioequivalent to the reference formulation (Brilinta) and well tolerated in healthy subjects.
Answers are grounded in this paper and cite their sources.
Supports generic ticagrelor substitution in practice; confirms bioequivalence to Brilinta in healthy subjects.
Objective: To investigate the Bioequivalence of Anplag® 90mg (Ticagrelor) tablet and Brilinta® 90 mg (Ticagrelor) tablet under fasting conditions in healthy Pakistani subjects. Method: This was an open-label, cross-over, randomized, single-dose, two-period, single-center Bioequivalence Study conducted at Center of Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, University of Karachi, Karachi, Pakistan from September 2020 to January 2021. This was an open-label, randomized, single-dose, two-period, cross-over Bioequivalence Study. After randomization, a single dose of Ticagrelor 90mg tablet (test or reference drug) were administered orally in 1:1 ratio to each subject under fasting conditions. Seven days washout period was kept between the two periods in order to avoid carry over. Blood samples were then taken up to 48th hours post-dose. Point estimates and 90% confidence intervals (CI) for the ratio of the log-transformed values were calculated. Bioequivalence assessment of both, the reference and the test drugs were based on the primary Pharmacokinetic PK metrics including peak maximum concentration (Cmax), area under the curve (AUC) from zero to last quantifiable concentration (AUClast), and AUC from zero to infinity (AUCtotal) after log-transformation of data with ANOVA. In this bioequivalence study, the primary pharmacokinetic parameters were assessed for both Ticagrelor and its Active Metabolite (AR-C124910XX). Safety endpoints were evaluated by monitoring adverse events (AEs). Results: The 90% Confidence Intervals (CIs) of the Geometric Mean Ratio for primary PK parameters including Cmax, AUClast, and AUCtotal all were within the accepted bioequivalence range of 80%- 125%. In the current study, no serious adverse events were reported. Conclusion: Our results showed that the two tested formulations of Ticagrelor tablets were bioequivalent and well tolerated. Trial Registration: ClinicalTrials.gov Identifier: NCT04941196. doi: https://doi.org/10.12669/pjms.39.6.8203 How to cite this: Hashmi N, Jawaid M, Shah MR. Bioequivalence assessment of two Ticagrelor formulations under fasting condition in healthy Pakistani subjects. Pak J Med Sci. 2023;39(6):1647-1651. doi: https://doi.org/10.12669/pjms.39.6.8203 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
No takes yet. Share an insight, caveat, or question.
Hashmi et al. (2023) conducted an RCT in Healthy subjects (n=30). Ticagrelor (Anplag) vs. Ticagrelor (Brilinta) 90 mg was evaluated on Bioequivalence based on AUClast (h×ng/ml) (Ratio of Geometric Means 112.33%, 95% CI 106.63-118.35). The generic formulation of Ticagrelor (Anplag) was bioequivalent to the reference formulation (Brilinta), with the 90% confidence intervals for primary pharmacokinetic parameters including Cmax, AUClast, and AUCtotal all within the accepted 80%-125% range.
Synapse has enriched 10 related papers. Consider them for comparative context: